-
Xinghai Roundtable | ADCs Redefine First-Line Treatment in HER2+ mBC: Expert Insights on Sequencing, Strategy, and Retreatment Approaches
DB-09 Redefines the First-Line Standard in Advanced Disease Oncology Frontier: The DB-09 study presented at ASCO 2025 has drawn significant attention and set a new benchmark for median PFS in…
-
Xinghai Roundtable | Spotlight on ASCO 2025: Advancing Precision Treatment Strategies for Early-Stage TNBC
Oncology Frontier: In the context of adjuvant therapy for early-stage TNBC, the Fudan Oncology team previously demonstrated the value of adding carboplatin in the PATTERN study (PCb vs. CEF-T). However,…
-
Professor Hua Yang: Advances in the Treatment of HER2-Positive Metastatic Breast Cancer and Strategies for Managing Brain Metastases
Fifth Bincheng Multidisciplinary Breast Cancer Conference Oncology Frontier: The DB-09 study was one of the highlights at ASCO 2025 and marked a breakthrough in the treatment of HER2-positive metastatic breast…
-
Roundtable Dialogue: Exploring Breast Cancer Radiotherapy Strategies and Multidisciplinary Innovation
Hubei Association of Radiation Oncology Physicians 2025 Academic Conference Oncology Frontier: Compared to conventional radiotherapy techniques, what are the significant clinical advantages of proton therapy in breast cancer? Professor Na…
-
Breakthrough in Bladder Cancer Treatment! Lin Tianxin and Chen Xu’s Team at Sun Yat-sen University First to Demonstrate Safety and Preliminary Efficacy of Intravesical Disitamab Vedotin in HER2-Positive High-Risk Non-Muscle-Invasive Bladder Cancer
A research team led by Professor Lin Tianxin and Professor Chen Xu from the Sun Yat-sen Memorial Hospital of Sun Yat-sen University has published clinical trial results in the prestigious journal MedComm, titled “Intravesical Disitamab Vedotin (RC48) for HER2-Expressing High-Risk Non-Muscle-Invasive Bladder Cancer: A Single-Arm, Dose–Escalation Phase I Trial Study.” This marks the world’s first…
-
ASCO China Voice | Professor Zhiming Li: First Phase I Clinical Study Results of a CCR8-Targeting Antibody Drug for Relapsed/Refractory Cutaneous T-Cell Lymphoma Announced
Cutaneous T-cell lymphoma (CTCL) is a heterogeneous malignant lymphoma originating from the skin and evolving from T-cells. It accounts for approximately 4% of non-Hodgkin lymphoma cases, classifying it as a…
-
Exclusive Interview with EHA President | Professor Martin Dreyling: Unmissable Breakthroughs in Myeloma, Leukemia, and Lymphoma at EHA 2025
The 2025 European Hematology Association (EHA) Annual Congress was successfully held from June 12 to 15 in Milan, Italy. Marking the 30th anniversary of the EHA, this year’s congress stood out as a major milestone, drawing over 15,000 experts and scholars from around the world with its global impact and groundbreaking research highlights. During the…
-
EHA Highlight | Professor Evangelos Terpos: A Comprehensive Upgrade in MM Management—What’s New in the 2025 EHA-EMN Clinical Guidelines?
At the 2025 Annual Congress of the European Hematology Association (EHA), the much-anticipated updated EHA-EMN clinical practice guidelines for multiple myeloma (MM) were officially released. Covering key areas such as diagnostic assessment, risk stratification, treatment pathways, and follow-up management, the new guidelines provide more forward-thinking and practical guidance for clinical implementation.
Connecting Medical Expertise through Media